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In the present historical review, we highlight several papers outlining contributions of the Framingham Heart Study
(FHS) over the span of nearly 7 decades to our understanding of the epidemiology of blood pressure (BP), atrial
ﬁbrillation, and genetic factors as they relate to cerebrovascular disease. In 1970, Framingham investigators led by
William Kannel explored the epidemiological relations of BP and its various components to risk of ischemic stroke
as well as hemorrhage, and they noted the greater impact of hypertension to risk of stroke compared with other
cardiovascular outcomes. Framingham investigators changed the prevalent concepts in terms of the contribution
of BP components to stroke risk; that is, they showed systolic pressure to be no less important a component for
stroke risk than the diastolic or mean arterial pressures. In addition, they challenged the notion that hypertension
was a normal consequence of increasing age, as connoted by the term essential hypertension. They also refuted
the idea that BP elevation in the elderly population is innocuous by demonstrating that increased stroke risk
persisted in advanced age in hypertensive persons. Thirty years later, the Framingham study attained long-term
follow-up of an entire generation of participants with excellent retention to follow-up, thus providing an
opportunity to study hypertension and risk of stroke in a general population sample. Framingham investigators
examined the effect of various BP components over a 50-year follow-up in normotensive and untreated
hypertensive individuals as regards stroke risk and showed the long-term importance of antecedent (midlife)
hypertension in future stroke risk. Similarly, by calling attention to the importance of chronic nonvalvular atrial
ﬁbrillation as a contributor to stroke, particularly in the elderly population, FHS investigators conﬁrmed the
clinical observations of the founder of stroke neurology, C. Miller Fisher, MD, who had made the clinical and
pathological association of atrial ﬁbrillation to stroke. Lastly, in the dawn of the era of individualized preventive
medicine, FHS is participating in the effort to further our understanding of the role of genetic factors to stroke
incidence. The contributions of FHS have been many and have shaped our understanding of the relation of BP,
atrial ﬁbrillation, and other risk factors to stroke risk, thereby setting the stage for clinical trials that demonstrated
how control of these risk contributors could prevent stroke and enable stroke prevention. FHS investigators are
collaborating with other geneticists and epidemiologists internationally to elucidate the role of genetic factors and
stroke susceptibility, which is likely to continue to shape the practice of preventive cardiovascular medicine.the National Institutes of
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j.gheart.2012.12.007The role of elevated blood pressure (BP) in causing
cerebrovascular disease was ﬁrst recognized in the 1920s.
Keith et al. [1] recognized symptoms arising from organic
lesions of the central nervous system in 29 of 81 patients in
their description of the syndrome of malignant hypertension.
Nonetheless, the relation of hypertension and cerebrovascular
disease, particularly ischemic stroke, remained unclear for
nearly 50 years. “Benign hypertension” was used to describe
hypertensive individuals and in the elderly population even
marked BP elevations were not considered pathological [2].
Subsequently, it was not until antihypertensive medications
became available in the mid to late 1960s that treatment of
extreme levels of diastolic hypertension was undertaken by
Fries [3], who demonstrated their effectiveness in reducing
cardiovascular disease, particularly stroke. Thus began the
series of clinical trials of patients with lower and lower dia-
stolic blood pressure (DBP) levels uniformly demonstrating
the efﬁcacy of BP reduction in stroke prevention. Based onGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 67-75epidemiological data provided by the Framingham Heart
Study (FHS), the National High Blood Pressure Education
Program was started in 1972 with the goal of educating
healthcare professionals and the public on the adverse impact
of hypertension [4]. The contribution of individual compo-
nents of BP was ﬁrst elucidated by Kannel et al. in 1970 [5] in
their landmark JAMA publication, which was recognized in
the ﬁrst “Report of the Joint National Committee on Detec-
tion, Evaluation, and Treatment of High Blood Pressure” in
1977, which used BP risk stratiﬁcation cut points deﬁned by
the FHS. Contributions of the FHS undoubtedly inﬂuenced
the understanding of the role of individual components of BP
as they relate to stroke. The scientiﬁc community eventually
embraced these concepts leading to evaluation and identiﬁ-
cation of effective therapies for individuals with much lower
BP values, less focus on the DBP than the systolic blood
pressure (SBP), and in hypertensive elderly people (above age
80 years) than previously was even considered.67
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for the conduct of epidemiological studies, achieving the
challenging task of close and comprehensive serial follow-
up of 3 generations of participants, with remarkable
participant retention at follow-up. The study began in
1948 with the enrollment of the original cohort, following
participants prospectively over more than 5 decades. This
has allowed for a more accurate understanding of the
natural history of participants with and without hyper-
tension, in terms of their risk of cerebrovascular disease,
clinically evident in the form of overt stroke, and in
subclinical stages. Since antihypertensive medication was
not used in clinical practice until the early 1970s, FHS
investigators were able to observe the impact of untreated
BP levels, including elevated levels, on a number of
outcomes including aspects of cognitive impairment [6].
An additional important contribution by investigators
of the Framingham study as it relates to stroke prevention
is the identiﬁcation of nonvalvular atrial ﬁbrillation (AF) as
a strong predictor of risk of stroke. Follow-up for an
extended period allowed for the evaluation of risk in
persons at a wide age range, showing the strong and
relative contributions of AF to stroke risk, particularly in
the elderly population.
More recently, the FHS has contributed signiﬁcantly to
elucidation of the role of genetic factors in stroke risk. The
careful ascertainment of stroke occurrence in the original and
offspring cohorts of the FHS permitted clariﬁcation of the
contribution of parental history of stroke, to stroke risk in
the offspring, and provided evidence that genetic factors
contribute substantially to stroke susceptibility. Advances in
genetic methods have been incorporated in the FHS, allow-
ing for the performance of genome-wide association studies
inwhich single nucleotide polymorphisms distributed across
the entire human genome can be assessed, without assuming
a priori hypothesis. FHS investigators directed a collaborative
effort to identify previously unknown gene variations in
common forms of stroke, leading to the identiﬁcation of
novel genes implied in stroke risk.
In the present historical review, we highlight several
selected FHS publications, over the course of nearly 7
decades, with regard to our understanding of the role of BP
in general, its individual components in particular (systolic,
diastolic, and pulse pressures), and AF as regards cere-
brovascular disease. (More comprehensive treatment of this
subject can be found elsewhere [7,8].) We also describe
a unique contribution provided by the FHS, emphasizing
the importance of antecedent BP measurements to stroke
risk prediction compared with the use of current BP
measurements and FHS contributions to the under-
standing of the role of genetic factors in stroke risk.BP AND ITS RELATION TO CEREBROVASCULAR
DISEASE
In 1970, Kannel et al. [9] reiterated hypertension as “the
most common and potent precursor of atherothromboticbrain infarction,” and they further suggested that “the key to
the prevention of CVAs would therefore, appear to be early
detection and control of hypertension.” Forty-two years
later, these statements remain true. In this report, Kannel
et al. describe the relationship of BP and its components to
stroke in 5,209 original cohort participants followed bien-
nially over 14 years for the occurrence of stroke in general
and ischemic stroke attributable to atherosclerotic brain
infarction (ABI), that is, brain infarction in the absence of an
obvious cardiac source of emboli, in particular. A casual BP,
representing the mean of 2 measurements recorded by
a physician was taken as the BP at the examination rather
than the basal or resting pressure, which was the measure
recommended at the time. Hypertension was arbitrarily
deﬁned as BP160/95 mm Hg, normotension as BP<140/
90 mm Hg, and borderline BP for measures within this
range; stroke was deﬁned according to conventional clinical
criteria. The method of surveillance for occurrence of stroke
included a brief neurological exam during the biennial
examination, conﬁrmation of cases by a neurologist in
consultation, and examination of study participants
admitted with a presumptive or conﬁrmed diagnosis of
stroke to the only local hospital in Framingham (since
1965). Surviving participants were followed regularly after
the stroke and in cases of death; all pertinent information
concerning circumstances of death was reviewed to deter-
mine if stroke was the cause of death. Further information
was gathered by interview of participants regarding the
occurrence of stroke in their spouse. The investigators tested
the accuracy of their stroke detection methods in a random
subset of 263 participants who underwent detailed neuro-
logical evaluation at the time of their biennial examination,
and they uncovered no additional cases of stroke.
Retention of participants at follow-up was impressive
with less than 2% lost to follow-up in 14 years. During this
period, 135 participants developed strokes (65 men, 70
women), with 86 considered ABI (39 men, 47 women).
ABI incidence increased with age in both men and women,
with women reﬂecting increased incidence in the older age
groups and men reﬂecting predominance at younger ages
(Fig. 1). Another important observation in this study is the
ﬁnding that the incidence of stroke in hypertensive indi-
viduals (with the BP cut points deﬁned here) versus in
normotensive participants was much higher than the
incidence of coronary heart disease in hypertensive
compared to normotensive participants (Fig. 2). FHS
investigators also noted sex differences in stroke rates
compared with coronary artery disease and peripheral
arterial disease, where there is a male predominance and
a closing gap between sexes with advancing age. Women
had similar rates of coronary artery disease and ABI,
whereas men had greater incidence of coronary artery
disease than ABI. Risk of stroke was distinctly related to BP
status at initial examination. Contrary to the prevailing
notion, the relative risk of intracranial hemorrhage (intra-
cerebral or subarachnoid hemorrhage) and ABI was not
different in relation to BP level.GLOBAL HEART, VOL. 8, NO. 1, 2013
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FIGURE 3. Risk of atherosclerotic brain infarction
(14 years) according to systolic and diastolic blood
pressure. Men and women ages 30 to 62 years at entry.
Reprinted, with permission, from Kannel et al. [9].
FIGURE 1. Prevalence of hypertension and incidence of
atherothrombotic brain infarction by age and sex. Men
and women ages 30 to 62 years at entry. Reprinted, with
permission, from Kannel et al. [9].
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ARTERIAL PRESSURE IN OCCURRENCE OF ABI
The investigators examined the relation of each BP
component to ABI, observing that the gradient of ABI risk
was similar according to SBP ﬁrst and then DBP. Age-
adjusted analysis in the entire population sample dis-
closed several crucial observations: 1) No critical level of BP
is evident, the risk “being simply proportional to the level
from the lowest to the highest recorded”; and 2) “gradients
for SBP and DBP are quite similar with nothing to suggest
a closer relation to DBP” (Fig. 3). In addition, BP—SBP or
DBP—was a more powerful discriminator of stroke risk
than was any of the other major cardiovascular conse-
quences except for congestive heart failure. In fact, the risk
estimates were nearly twice as high for stroke as for
coronary heart disease, especially for men (Table 1). In this
report, FHS investigators also studied the role of meanFIGURE 2. Risk of cardiovascular disease (14 years)
according to blood pressure status. Men ages 30 to 62
years at entry. Reprinted, with permission, from Kannel
et al. [9].
GLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 67-75arterial pressure (MAP), showing that MAP discriminated
cases no better than SBP alone, but it was better than DBP.
In women, MAP seemed to discriminate as well as SBP.
Kannel and colleagues reached an important conclusion
that again challenged prevalent notions at the time, “this
gives no indication that SBP plays a minor role in ABI.”
They reasoned that MAP predicts no better than SBP alone,
likely deriving from the fact that both are highly correlated
and SBP is more accurately measured than DBP is. A third
observation opposing prevalent notions at the time was
that “there was no tendency of the impact of SBP to
decrease with age in either sex,” thus, disproving the
notion that elevated BP in the elderly is innocuous.
When comparing SBP and DBP as stroke risk predictors
combined versus either component alone, the discrimina-
tory analysis showed that when used together, both ach-
ieved little more than SBP alone; DBP discriminated no
better than SBP; and there was no decrement with age.
Furthermore, the investigators discussed the role of con-
founding factors on the relation of interest, thus pioneering
underlying concepts in multivariable analysis. The report
studied the roles of obesity, diabetes, and gout in the
observations noted previously. Excluding individuals with
these conditions, the investigators observed that there was
a distinct residual gradient of risk proportional to the BP
level. Similarly, in subjects without left ventricular hyper-
trophy or congestive heart failure, risk of ABI was distinctly
related to BP alone. Lipid levels were also studied, ﬁnding
that little was added to the risk of ABI by lipid level
(cholesterol and triglycerides); though they acknowledged
that subgroup analysis was limited by small numbers.
The conclusions of this study changed existent
conceptions of the relation of BP and cerebrovascular
disease at the time and provided the foundations for
preventive interventions in clinical practice: “though
treatment thresholds are arbitrary, this was [the] ﬁrst step
to guide clinicians in decisions to treat patients in order to
reduce risk of stroke.” Although not directly evaluated in69
TABLE 1. Average of standardized mean deviations of systolic blood pressure in men and women 38 to 69 years of age developing
disease versus those remaining free of disease
Coronary Heart Disease
Mean Deviation
Intermittent Claudication
Mean Deviation
Cardiovascular Accident
Mean Deviation
Congestive Heart Failure
Mean Deviation
n Systolic Diastolic n Systolic Diastolic n Systolic Diastolic n Systolic Diastolic
Men 252 0.41 0.29 58 0.60 0.15 53 0.83 0.61 44 0.92 0.62
Women 135 0.68 0.39 30 0.23 0.03 53 0.81 0.70 30 0.93 0.65
Standardized mean deviation ¼ (mean pressure of casesemean pressure of noncases)/population SD. This table summarizes the age-speciﬁc mean
deviations. The differences between disease categories are not accounted for by the differences in age distribution. Mean deviations were not found
to vary appreciably with age.
Reprinted, with permission, from Kannel et al. [9].
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70this report, based on the strength of the relation of BP and
stroke, the investigators correctly estimated that even labile
BP (as opposed to ﬁxed) is likely to play a role. They also
provided convincing evidence contrasting the existing
notion that the cerebrovascular consequences of BP derive
only from the DBP component. This analysis showed that
both components were not better predictors than SBP
alone. The notion that SBP represented aortic rigidity and
a natural, innocuous consequence of aging was dispelled.
The investigators provided further insight into the
hypothesis concerning the mechanism by which hyper-
tension affects the occurrence of stroke, including
mechanical damage of vessels and impairment of cardiac
function, suggested by the stronger relation of hyperten-
sion to stroke than other cardiovascular outcomes. Lastly,
acknowledging the results of one of the ﬁrst clinical trials
showing beneﬁts of BP lowering on stroke risk reduction
[3], Kannel et al. made a statement that would only be truly
understood decades later: “asymptomatic mild hyperten-
sion is far from innocuous even in the elderly and treat-
ment should begin early.”INTERIM RECOGNITION OF THE FHS
CONTRIBUTION
In 1996, a perspective paper in JAMA called attention to
the relevance of the 1970 FHS publication [10]. The
editorial highlighted several important observations made
in the study, which emphasizes a crucial function of the
FHS over time: providing clinicians in the medical
community with a practical contribution for the care of
patients on a daily basis. This paper highlights some such
contributions: 1) classiﬁcation of individuals on the basis of
BP recordings made during a routine clinical examination
making it possible for clinicians to extrapolate this practice
to medical care; 2) provision of one of the earliest classi-
ﬁcation systems for stroke etiology using available knowl-
edge and techniques; and 3) elucidation of the contribution
of individual components of BP to stroke risk. Again,
noting the fact that while at the time it was believed that
DBP played a more important role in causing hypertensive
organ damage, the investigators demonstrated ratherclearly that this was not the case for stroke, where SBP was
more strongly related than DBP.
The investigator noted a number of the predictions of
FHS investigators that had stood the test of time, with
multiple subsequent studies showing the same results: for
instance, by the Seven Countries Study. Dr. Kannel et al.
correctly implied that the treatment of hypertension would
reduce stroke incidence; this has been proved through
multiple randomized clinical trials and is now a most
essential component of all practice guidelines for stroke
prevention. No threshold effects were discerned, as stroke
risk increases steeply with BP over the whole range of BP.
Current practice guidelines by the American Heart Asso-
ciation for secondary prevention of stroke implicitly inte-
grate this concept when recommending that “an absolute
target BP level and reduction are uncertain and should be
individualized, but beneﬁt has been associated with an
average reduction of approximately 10/5 mm Hg, and
normal BP levels have been deﬁned as <120/80 mm Hg by
JNC 7” [11].
ANTECEDENT (MIDLIFE) HYPERTENSION AND RISK
OF STROKE
The prospective, long-term, and meticulous follow-up of
FHS participants over decades has provided FHS investi-
gators with the opportunity to relate past BP measurements
in the prediction of future stroke, after accounting for the
inﬂuence of current BP measures, and in currently
normotensive individuals [12]. Follow-up for an extended
period with such high retention of participants and
comprehensive assessments attests to the reliability of the
results in this report. In this paper, the study spanned
a period of 50 years, including 5,197 original cohort
participants free of prevalent stroke at the index exami-
nation. The role of each component of BP—systolic, dia-
stolic, and pulse pressure (PP)—was assessed to evaluate
for differential contribution of past BP measures to future
risk of ischemic stroke. The investigators considered 3
aspects of BP: 1) current BP at time of prediction, which
occurred at a baseline age of 60, 70, or 80 years; 2) recent
past BP in the decade preceding risk prediction; and 3)
remote past BP, 10 to 20 years before risk prediction.GLOBAL HEART, VOL. 8, NO. 1, 2013
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Ascertainment of ischemic stroke now included brain
imaging with magnetic resonance imaging or computed
tomography performed in 85% of all strokes and used
autopsy data when available. Stroke was classiﬁed as ABI in
the absence of a cardiac source of emboli and included
3 etiological groups: large artery infarct, lacunar infarcts,
and infarcts of unknown origin. The analysis evaluated the
effect of 1 SD change in current BP (SBP, DBP, or PP) on
the 10-year stroke risk in 60-, 70-, and 80-year-old
participants without adjusting for past BP measurements.
Subsequent analysis was additionally adjusted for current
BP, and the incremental prognostic utility of remote BP
was assessed similarly. To minimize effects of regression
dilution bias, given that the investigators used multiple
measurements of antecedent BP (2 to 5 BP readings
depending on the number of available examinations during
the decade of interest), they randomly repeated the analysis
using BP recorded at single random examinations within
the decade of interest to represent antecedent BP. Addi-
tional secondary analysis included stratiﬁed analysis
according to current BP status (hypertensive versus non-
hypertensive), by treatment status (yes versus no), and by
year when baseline age was reached (pre- or post-1975).
The study included 3,761 subjects reaching the age of
60 years free of stroke with information available for
analysis, 3,049 subjects reaching age of 70 years, and 1,203
reaching age 80 years. The mean SBP and PP increased
with age, and mean DBP decreased with age. DBP
decreasing with age reﬂects a contribution of the FHS to
the understanding of the changes in BP with age and the
underlying pathophysiology of hypertension. The propor-
tion of subjects taking antihypertensive medications
increased with age and was over 40% in participants 80
years of age at baseline exam. This also indirectly reﬂects
the inﬂuence of the FHS on medical practice. In prior
decades, persons in this age group would not have been
considered for antihypertensive therapy. There were 830
completed strokes during the 50-year period in 5,197
participants: 740 of the strokes occurred between ages 60
and 89 years; 521 occurred in subjects who attended
within 1 year of biennial exam and who could give reliable
information for current BP at baseline. Regarding current
BP measurements, participants with higher levels of BP at
the time of risk prediction showed an increased 10-year
risk of stroke for all BP components—SBP, DBP, and PP.
The effect was strongest at 60 years of age and weakest at
80 years of age. In the 80-year-old group, the risk was
greater for SBP and PP than for DBP.
In analyses adjusted for current BP, antecedent BP
demonstrated a further increase in the 10-year risk of
stroke (Table 2). The effect was signiﬁcant and ranged
between 68% to 92% increase at age 60 years, 14% to 72%
increase risk at age 70 years, and up to 32% at age 80 years.
Similar effects were noted as regards remote antecedent BP.
The investigators noted that the relationships observed
varied with age and sex. The effect of current and ante-
cedent BP was most powerful at age 60 years, with riskGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 67-75estimates being lower at ages 70 and 80 years. In 70-year-
old men, SBP and PP were more informative than DBP was.
Recent or current DBP was not signiﬁcant in men 70 years
of age, but remote DBP remained signiﬁcantly predictive.
In the speciﬁed secondary analyses, the relations of ante-
cedent BP and risk of stroke persisted even when a single
random BP measure was used, though the effect size
decreased. There was no signiﬁcant effect modiﬁcation in
stratiﬁed analysis by sex or antihypertensive medication
use, although the subgroup analysis had lower statistical
power due to small numbers in the subgroups. The effect
of recent antecedent BP remained signiﬁcant in stratiﬁed
analysis by time period pre- or post-1975.
This paper also showed that 28% of all ABI occurred
on subjects whose current BP was in the nonhypertensive
range; that is, even if BP is normal at the time of the clinic
visit, antecedent hypertension (both recent and remote)
could be used to identify those who remain at high risk of
future stroke. In addition, risk estimates of antecedent BP
span a 30-year period of observation for risk estimation,
which underscores the importance of BP assessments in
midlife to affect risk of stroke even 30 years later. Given
that life expectancy is increasing in the United States, the
implications of this study in public health are highly
signiﬁcant. BP assessment and resulting treatment modiﬁ-
cations for patients during midlife to prevent future stroke
needs to be emphasized.AF AND RISK OF STROKE
An additional contribution of the Framingham study for
stroke prevention is the elucidation of nonvalvular AF as an
independent strong risk factor for stroke. In 1951, Fisher
and Adams [13] made the clinical and pathological asso-
ciation of AF to stroke. Although valvular AF with rheu-
matic heart disease had been long recognized as the basis
for cerebral embolism, Dr. Fisher’s observation strongly
suggested that established AF in the absence of mitral
stenosis was an important source for cerebral embolism. In
1978, Wolf et al. [14] published a seminal article relating
nonvalvular AF to stroke risk. Following the procedures
previously outlined for the surveillance of stroke in the
Framingham study, they determined incidence rates of
stroke in 4,969 participants free of AF and among partic-
ipants with AF, in those with nonvalvular and valvular AF.
The observed-to-expected ratio of stroke incidence was
provided and adjusted for BP and age in each sex. After 24
years of follow-up, 345 strokes occurred (168 men, 177
women). ABI accounted for 59% of all strokes; cerebral
embolism accounted for 14%; and the remaining were
classiﬁed as other 3%, TIA 9%, intracerebral hemorrhage
5%, and subarachnoid hemorrhage 10%.
The investigators found that independent of age and
hypertension, participants with nonvalvular AF had stroke
incidence rates 5.6-fold greater than those without AF. The
paper also details the clinical features of an embolic stroke,
which has guided clinicians in making judgments for the71
TABLE 2. Regression of ischemic stroke incidence on current and antecedent BP measurements, by BP component
BP Measurement
Women
SBP DBP PP
Baseline age at 60 yrs
71 ischemic strokes in 2,197 subjects
Current age, 60 yrs 2.03 (1.69e2.44) 1.85 (1.56e2.21) 1.78 (1.48e2.15)
Recent past: mean age, 50e59 yrs* 1.68 (1.25e2.25) 1.78 (1.33e2.38) 1.80 (1.35e2.42)
Remote past: mean age, 40e49 yrs* 1.48 (1.07e2.07) 1.57 (1.13e2.17) 1.60 (1.08e2.36)
Baseline age at 70 yrs
130 ischemic strokes in 1,875 subjects
Current age, 70 yrs 1.67 (1.44e1.94) 1.49 (1.27e1.75) 1.53 (1.31e1.78)
Recent past: mean age, 60e69 yrs* 1.66 (1.28e2.14) 1.44 (1.11e1.88) 1.72 (1.31e2.27)
Remote past: mean age, 50e59 yrs* 1.41 (1.17e1.69) 1.47 (1.23e1.75) 1.52 (1.20e1.93)
Baseline age at 80 yrs
81 ischemic strokes in 791 subjects
Current age, 80 yrs 1.40 (1.13e1.73) 1.14 (0.91e1.43) 1.37 (1.10e1.69)
Recent past: mean age, 70e79 yrs* 1.19 (0.84e1.70) 1.21 (0.86e1.70) 1.12 (0.75e1.67)
Remote past: mean age, 60e69 yrs* 1.05 (0.79e1.42) 1.14 (0.86e1.51) 1.01 (0.69e1.49)
Data are given as relative risk (95% conﬁdence interval). All relative risks are presented per SD change in BP component at baseline age and are
adjusted for diabetes mellitus and smoking status.
BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
* Relative risks for antecedent BP measurements are also adjusted for current (baseline) BP measurements.
Reprinted, with permission, from Seshadri et al. [12].
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72mechanism of stroke: “abrupt onset, often while active, of
focal neurologic dysfunction, reaching its maximum in
moments,” and the neuropathological ﬁndings consistent
with cerebral embolism, validating their clinical impressions.
Eleven of 20 participants with idiopathic AF died, showing
the high mortality carried by such strokes, and 6 underwent
neuropathological examination of the brain: “cerebral infarct
corresponded in location and age to the clinical event.
Infarction was multiple in one case and associated with atrial
thrombus and an old splenic infarct in another. The arteries
were patent in two cases, and in one of these the infarct was
hemorrhagic.”
A follow-up publication by Wolf et al. elucidated the
relations of age and risk of stroke in participants with AF
[15]. After attaining 30 years of follow-up, the investigators
compared stroke incidence rates in participants who
developed AF versus those without AF. AF-associated
strokes represented 14.7% of the total 462 initial stroke
events during the observation period. Incident AF was
detected in 303 participants (163 men, 140 women) and
increased with age in both sexes from 0.4 and 0.0 per
1,000 at age 30 to 39 years to 45.9 and 35.8 per 1,000 at
age 80 to 89 years in men and women, respectively.
Strokes occurred in 68 persons with AF and in 394
participants without AF. The 2-year, age-speciﬁc incidence
rates of stroke increased parallel with age. The proportion
of AF-associated stroke to total stroke was clearly related to
age, increasing steadily from 6.7% for ages 50 to 59 yearsto 36.2% for ages 80 to 89 years. This report also notes the
strength of effect of AF, compared with other prominent
risk factors including hypertension, heart failure, and
coronary heart disease, on risk of stroke in the elderly
population. Whereas all of these factors contributed inde-
pendently to stroke risk in younger participants, their effect
declined with age, and in participants between ages 80 and
89 years, only AF remained a signiﬁcant risk factor after
accounting for the others. The risk of stroke attributed to
AF increased with age, from 7.3% in subjects ages 60 to 69
years to 30.8% in those ages 80 to 89 years, even after
adjusting for the effect of SBP, heart failure, and coronary
heart disease. Table 3 shows the proportion of strokes
attributed to AF compared with those attributed to coro-
nary heart disease and heart failure. Because there is
increasing longevity in the U.S. population, and now there
are several available treatments for stroke risk reduction in
patients with AF, the relevance of FHS contributions to
reduce the burden of stroke, particularly in the elderly
population are obvious.GENETIC RISK FACTORS AND STROKE RISK
The careful prospective ascertainment of stroke occur-
rence and methodic classiﬁcation of stroke type in the
FHS original and offspring cohorts over an extended
period gave the FHS a unique advantage to clarify the role
of family history on stroke risk. Previously, parentalGLOBAL HEART, VOL. 8, NO. 1, 2013
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Men
SBP DBP PP
Baseline age at 60 yrs
71 ischemic strokes in 1,564 subjects
1.39 (1.12e1.72) 1.42 (1.15e1.74) 1.23 (0.98e1.53)
1.92 (1.39e2.66) 1.73 (1.26e2.38) 1.82 (1.14e2.58)
1.54 (0.96e2.45) 1.30 (0.88e1.91) 1.50 (0.88e2.56)
Baseline age at 70 yrs
101 ischemic strokes in 1,174 subjects
1.53 (1.28e1.83) 1.08 (0.89e1.31) 1.66 (1.39e1.99)
1.30 (0.97e1.75) 1.14 (0.84e1.54) 1.37 (0.99e1.90)
1.45 (1.14e1.86) 1.42 (1.13e1.80) 1.51 (1.10e2.08)
Baseline age at 80 yrs
37 ischemic strokes in 412 subjects
1.25 (0.92e1.71) 0.99 (0.71e1.38) 1.30 (0.95e1.77)
1.25 (0.76e2.04) 1.32 (0.79e2.21) 1.12 (0.67e1.87)
1.25 (0.81e1.93) 1.20 (0.80e1.79) 1.26 (0.74e2.16)
TABLE 2. (Continued)
gREVIEWjhistory of stroke remained a controversial factor in terms
of its contribution to stroke risk in the offspring, mostly
due to several issues leading to misclassiﬁcation of stroke
events and limitations in detection of stroke events. In
a study including 3,443 stroke-free Framingham offspring
participants with veriﬁed parental stroke status by 65
years of age, incident stroke was ascertained in the
offspring over a follow-up of 8 years after a baseline
examination, yielding up to 11,029 person-observation
periods (77,534 person-years) [16]. Stroke was docu-
mented in 106 parents and 128 offspring participants,
with 74 parental and 106 offspring strokes being ischemic.
In multivariable Cox regression analyses adjusted for age,
sex, sibship, and baseline stroke risk factors, the investi-
gators observed that parental history of both all stroke in
general and ischemic subtype in particular was associatedTABLE 3. Percentage of strokes attributed to nonrheumatic chronic
and women combined
Age Group, yrs
A
Coronary Heart Disease Cardiac
50e59 19.5 (9.9e29.1) 9.4 (3
60e69 17.2 (9.3e25.3) 9.1 (4
70e79 19.5 (9.9e29.1) 13.9 (7
80e89 10.6 (0.0e29.5) 11.1 (0
Thirty-year follow-up of the Framingham study.
*Signiﬁcant increase with age before and after adjusting for systolic bloo
intervals.
yInsufﬁcient data.
Reprinted, with permission, from Wolf et al. [15].
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in the offspring (hazard ratio [HR]: 2.79, 95% conﬁdence
interval [CI]: 1.68 to 4.66; p < 0.001 for all stroke; and
HR: 3.15, 95% CI: 1.69 to 5.88; p < 0.001 for ischemic
stroke). The higher risk in offspring with parental stroke
was seen across all quintiles of baseline Framingham
Stroke Risk Proﬁle score, showing the independent
contribution of parental history of stroke. Both paternal
and maternal histories of stroke were related to risk of
stroke in the offspring. This study exempliﬁed a major
strength of the FHS, which is the careful assessment of
3 generations of participants for incident stroke, and
provided important evidence of the role of genetic factors
in stroke risk in the offspring.
The advances in technologies for mapping of the human
genome have been incorporated in the FHS, allowing for theatrial ﬁbrillation, coronary heart disease, and cardiac failure, men
ttribution of Strokes, %
Failure
Nonrheumatic Chronic Atrial Fibrillation*
Unadjusted Adjusted
.1e15.7) 6.2 (0.9e11.5) —y
.2e14.0) 6.4 (2.1e10.7) 7.3 (2.8e11.8)
.6e20.2) 17.4 (10.5e24.3) 16.5 (9.8e23.2)
.0e23.1) 28.9 (14.0e43.8) 30.8 (15.1e46.5)
d pressure (p < 0.05). Numbers in parentheses are 95% conﬁdence
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determinants of stroke. Given that stroke is a complex
disease, where multiple genetic risk factors are likely each
contributing in small amounts to stroke risk, large samples
are required to detect such genetic factors. FHS investigators
have led a collaborative effort along with 4 other major
epidemiological studies, the CHARGE (Cohorts for Heart
and Aging Research in Genomic Epidemiology)econsor-
tium, to attain a sufﬁcient sample size to study the under-
lying genetic determinants of the most common stroke
types. In a recent publication [17], a genome-wide associ-
ation study was conducted including 19,602 white persons
(mean [ SD] age: 63  8 years) in the context of the
CHARGE consortium. A total of 1,544 incident strokes
(1,164 ischemic strokes) occurred over a period of 11 years.
The investigators identiﬁed 2 intergenic single-nucleotide
polymorphisms on chromosome 12p13 that were associ-
ated with stroke at genome-wide association study signiﬁ-
cance levels (p < 5  108). The single nucleotide
polymorphisms were in proximity to the NINJ2 gene, which
encodes an adhesion molecule expressed in glia and shows
increased expression after nerve injury, and the WINK1
gene, which has been implicated in BP levels and severity of
hypertension. The risk of total (i.e., all types) and ischemic
stroke was increased with HR of 1.30 (95% CI: 1.19 to 1.42)
and 1.33 (95% CI: 1.21 to 1.47), respectively, with pop-
ulation attributable risks of 11% and 12% total stroke and
14% to 17% for ischemic stroke in the discovery cohorts.
The results were replicated in 3 independent cohorts,
including a cohort of 2,430 black persons with 215 incident
strokes (191 ischemic strokes), another cohort of 574 black
persons with 85 incident strokes (68 ischemic strokes), and
652 Dutch persons with ischemic stroke and 3,613 unaf-
fected persons.
Genetic epidemiology methods and knowledge are
advancing at a fast pace, and the FHS is at the forefront of
such research efforts. FHS investigators will continue to
provide much-needed insight into the role of genetic
factors in risk of stroke in general, and speciﬁc stroke
subtypes in particular, which will enable eventual use of
this information in preventive clinical care.CLINICAL PERSPECTIVE
Undoubtedly, the FHS has contributed to, and in many
ways led, the practice of preventive cardiovascular
medicine. The epidemiological observations made over
the course of nearly 7 decades of follow-up have clariﬁed
erroneous concepts in the medical community and
introduced many others to shape clinical practice. The
case of the relation of BP and cerebrovascular disease is
no different. The reports in the ﬁrst 20 to 30 years of the
FHS contributed greatly to dispel erroneous concepts and
to advance our knowledge of the relation between various
BP components and stroke in general and ABI in partic-
ular. Speciﬁcally, FHS data showed the following:
1) Mean SBP is more closely related to stroke risk thanDBP is. Kannel et al. disproved the existent concept that
DBP was the main BP component causing hypertensive
organ damage by showing that the risk of ABI was more
strongly related to SBP than to DBP. Further, MAP or
DBP, compared with SBP alone, did not add signiﬁcantly
to stroke risk prediction. Though both BP components
were thought to cause vascular damage, it was shown that
SBP was the main driving force as regards stroke risk.
2) The work by Kannel et al. elucidated the modiﬁcations
of the relation of hypertension and stroke risk by sex and
age. The risk increased for both men and women with
age, but there was a change with increasing age such that
men had higher risk in middle age and women had
higher risk in advanced age. In addition, the observation
that the impact of BP in stroke risk did not decrease with
age clearly showed that hypertension is not innocuous in
the elderly population. 3) Kannel et al. also clariﬁed the
absence of a critical threshold in the relation of BP and
stroke risk, showing that there is a continuum in risk for
both men and women; indeed, the risk of stroke has been
shown to increase almost linearly with BP level, even with
measurements considered normal. At the same time, the
investigators noted that hypertension is more strongly
associated with risk of stroke than with risk of other
major cardiovascular outcomes including coronary heart
disease and peripheral arterial disease.
In 2001, using data acquired over 50 years into the
study, FHS investigators published a remarkable study
showing that: 1) midlife detection of elevated BP affects
future stroke risk even 3 decades later; and 2) antecedent
hypertension is helpful to further stratify risk of persons
with current normotension. The risk of stroke was
increased by antecedent hypertension (recent and remote)
after adjusting for current BP measurements, and in
normotensive persons, the risk of stroke was signiﬁcantly
higher in the presence of antecedent hypertension. For
a practicing clinician, the beneﬁts of these observations are
clear: they demonstrate long-term effects of BP, highlight
the importance of BP surveillance and early detection of
hypertension, and can be used for patient education, which
is essential for effective preventive medicine. In addition,
this paper emphasizes the fact that, regardless of age,
history of antecedent hypertension aids in the selection of
patients for treatment and stroke risk reduction. In 2008,
about 60 years into the FHS and 4 decades following
Kannel et al.’s initial report, the HYVET (Hypertension
in the Very Elderly Trial) was published [18], and it
demonstrated that treatment of hypertensive persons older
than 80 years reduces the risk of stroke, death from stroke,
and other cardiovascular outcomes and is well tolerated.
Concerning the role of AF in stroke, the Framingham
study investigators have provided crucial epidemiological
data, proving the strong association of cerebral embolism
with nonvalvular AF, and further clarifying the age and sex
relations between nonvalvular AF and incident stroke.
Importantly, the Framingham investigators noted the
increasing incidence of AF with age and the higherGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 67-75
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proportion of strokes attributed to AF in the elderly pop-
ulation. These observations contributed signiﬁcantly to
subsequent clinical trials of stroke prevention treatments in
persons with AF. Given the increasing population reaching
older groups in the United States, and the now widely
available treatments for stroke prevention in patients with
AF, the Framingham study observations regarding the role
of AF in stroke in the elderly population are of major
public health importance. The original Framingham papers
have provided major contributions to the shift in the
practice of cerebrovascular preventive medicine. Current
treatment guidelines are founded on data from the Fra-
mingham study as regards hypertension and stroke
prevention and are heavily inﬂuenced by Framingham data
concerning AF and prevention of stroke, and they set the
stage for the future of preventive cerebrovascular medicine.
Lastly, in the wake of the era of individualized
preventive medicine, FHS investigators are leading the way
to further our understanding of the contribution of genetic
factors to stroke susceptibility. Important advances have
been made, and continued efforts will likely help elucidate
how information about genetic factors can be used in
clinical practice to prevent cerebrovascular disease in
individuals.
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